CONCEPT NOTE

Can We Afford the Current Model of Medical Innovation?
Towards New Models of Innovation

Themes

- The cost and financing of medical innovation
- EU Council Conclusions on Global Health
- The shared needs of North/South citizens
- The need for structural change
- New models of biomedical innovation
- De-linking R&D cost from price of medicines
- The financial crisis and health expenditure

18 November 2010, 09:00 – 13:30
Room (TBC), European Parliament, Brussels

Hosts

Thijs Berman MEP, Progressive Alliance of Socialists & Democrats
Eva Joly MEP, The Greens/EFA

NGO Sponsors

Health Action International (HAI) Europe
IQ Sensato Group
Knowledge Ecology International (KEI)
Oxfam International
TransAtlantic Consumer Dialogue (TACD)
CONCEPT NOTE

Event summary

At present, we suffer from a lack of public health-driven medical innovation and of global access to essential medicines. At the same time in the EU and around the world, governments are incapable of facing the growing cost of health care of which medicine prices are an important factor. To respond to global health needs new models of affordable and socially useful medical innovation are needed.

The EU Council Conclusions on Global Health in May 2010 have called for further exploration of innovation models that de-link the cost of R&D from the price of medicines. At the same time, a resolution was adopted at the World Health Assembly encouraging member States to develop new models of biomedical innovation in order to ensure both Access and Innovation.

The objective of this meeting is the practical design and implementation of EU policy and budget decisions to support new models of biomedical innovation that ensure both health-driven medical innovation and affordable access to life-saving products.

The recent price cuts of patented medicines by various European governments have shown that the sustainability of the current innovation model is a real issue not only for developing countries, but also for EU Member States. It is increasingly obvious that the issue of universal access to medical products should be integrated into the early stages of the innovation process.

The panels will feature experts, NGO representatives, scientists and academics, with input from the pharmaceutical industry, the EU Commission and country delegates. There will be two public panels in the morning, followed by an invitation-only technical workshop in the afternoon where the participants will formulate specific recommendations for EU policy changes and the launching of pilot projects.

PRELIMINARY PROGRAMME

09.00: Welcome: Eva Joly MEP
09.10: Introduction: Ruxandra Draghia-Akli (DG Research, EU Commission)

PANEL ONE - THE CURRENT MODEL OF INNOVATION HAS REACHED ITS LIMITS
Moderator: Carl Schlyter MEP

09.25: The Status Quo of Innovation and Access, and Responses to the Financial Crisis: David Hammerstein (TACD)
09.35: Intellectual Property, Competition, and Access in Europe: Sophie Bloemen (HAI)
09.45: How the Current Model is Failing Europe: Jorg Schaaber (ISDB)
CONCEPT NOTE

10.05: Response: Bernard Pecoul (DNDi)

10.15: Response: Maria Iglesia Gomez (DG SANCO, EU Commission)

10.25: Discussion (30 minutes)

10.55: COFFEE BREAK

PANEL TWO - NEW MODELS FOR INNOVATION AND ACCESS TO MEDICINES
Moderator: Thijs Berman MEP

11.05: Policy framework for new models on Innovation and Access: Judit Rius Sanjuan (KEI)

11.10: Towards new models of innovation: future work in WHO: Zafar Mirza (WHO)


11.30: Biomedical Research & Development Treaty: Sisule Musungu (IQ Sensato)

11.40: De-linking Research Costs from the Price of Medicines: Médecins Sans Frontières

11.50: COFFEE BREAK

12.00: The Prize Fund Model for Innovation and Access: James Love (KEI)

12.10: New innovation models from the South I- Proposals for Latin America: Francisco Rossi (Alianza LAC-Global)

12.20: New innovation models from the South II- Open Source Drug Discovery: Samir Brahmachari (CSIR India) (TBC)

12.30: Response: Robert Sebbag (Sanofi-Aventis)

12.40: Response: Ruxandra Draghia-Akli (DG Research, EU Commission)

12.50: Discussion (30 minutes)

13.20: Closing remarks: Thijs Berman MEP
Event summary

This expert workshop will discuss specific proposals to address problems with the current model of medical innovation, as discussed in the morning session.

Proposals would address one or more of the following issues: R&D funding and incentives that de-link the cost of R&D from the price of products; management of intellectual property rights to meet European and global public health needs; mechanisms to increase the sharing and access to scientific knowledge and data and the collaboration among researchers.

Participants will discuss proposals for alternatives to the current model of innovation, focusing on the technical and operational aspects of implementation for new models of medical innovation in the EU and developing countries. The invited participants have been selected to deliver the relevant issue expertise, policy experience, and institutional knowledge that will enable the meeting to generate specific and practicable policy recommendations.

In the workshop, possible pilot projects and policy initiatives will be presented in the context of the EU policy and participants will explore ways to effect the necessary changes through specific budget lines, programming etc. in EU institutions. Input from the invited experts will be crucial to refine and adjust the proposals. The sessions will rely on the expertise contributed by participants to deliver high-quality recommendations from the event.

The aim is to have specific pilot proposals* carried forward by MEPs, so that new models can be explored through the EU budget. As the Council Conclusions on Global Health of May 2010 has already established the exploration of models that de-link R&D costs from medicines prices as a goal, the recommendations from this workshop offer a unique opportunity to turn these conclusions into concrete EU policy.

*Draft proposals will be distributed to participants before the workshop.

14.30-18.00:

Chairs:

14.30-15.10: Session 1: Juan Garay DG DEV / Judit Rius Sanjuan- KEI
15.10-15.50: Session 2: Carl Schlyter MEP/ Rohit Malpani-Oxfam
15.50-16.30: Session 3: Thijs Berman MEP /Sophie Bloemen-HAI
16.30-18.00: Session 4: Thijs Berman MEP / Gaelle Krikorian-TACD
CONCEPT NOTE

Focus
How can EU policy and funding programmes accommodate changes and promote the implementation of the Global Health Council Conclusions and WHO Resolutions (with specific reference to a piece of legislation / budget / department etc.)

Topics
1. The TB Point of Care Diagnostic Prize. Presenter: Michelle Childs, MSF
2. Incentives for R&D gaps. Presenter: Bernard Pecoul, DNDi
3. Prizes for Cancer treatments and vaccines. Presenter: James Love, KEI
4. Incentives and mandates for Equitable Licensing
   a. Equitable licensing and European Framework programs. Presenter: Christian Wagner, Buko Pharma
   b. Open source dividends. Presenter: KEI
   c. Donor prize fund for HIV AIDS treatment. Presenter: KEI

Format
a) Session Presenter introduces the proposal & states the goal (implementing the proposal within specific EU policy architecture- budget, programming, responsibility, coordination etc.)

b) Session Presenter introduces (and elicits from experts) necessary considerations to achieve goal

c) Session Chairs coordinate the input from experts according to their area of knowledge/experience (Rapporteur to record key points/recommendations)

d) Session Presenter updates talking points/considerations based on expert input

e) Session Presenter puts forward draft recommendations* for achieving this goal

f) Session Chairs coordinate final selection and definitions of the recommendations

*Draft recommendations will be distributed before the workshop.

18.00-18.15: Closing remarks & Recap of Workshop Recommendations: Sisule Musungu, IQ Sensato